To date, Quvium has raised £2M+ that has been used for design and development purposes, securing intellectual property and operationalising the business.
We are now seeking £3.2M to complete our Series A investment, preferring to partner with an investment company which has proven experience of building growth businesses through their expertise in the healthcare and technology sectors.
We are finalising CE mark certification, MHRA Class I registration and will follow with a UK launch in 2018 targeting patients with COPD and children with poorly controlled asthma.
We will also be undertaking clinical trials as part of our strategy to supply to the NHS, quickly broaden the clinical scope of SONASURE to include other respiratory diseases and prepare and file a 510K submission in advance of a US launch.
If you are interested in investing, please contact us today by emailing firstname.lastname@example.org